Stephen Glover
Chief Executive Officer en ZYVERSA THERAPEUTICS, INC. .
Fortuna: 266 251 $ al 31/03/2024
Perfil
Stephen C.
Glover is the founder of ZyVersa Therapeutics Operating, Inc. (founded in 2014) where he holds the title of Chairman & Chief Executive Officer.
He was also the founder of Coherus BioSciences, Inc. (founded in 2010) where he held the title of Chief Business Officer from 2010 to 2013.
Additionally, he is the founder of ZyVersa Therapeutics, Inc. (founded in 2014) where he holds the titles of Chairman, President & Chief Executive Officer.
Mr. Glover is also the founder of Asclepius Life Sciences Fund LP.
Mr. Glover's current job(s) include being the Chairman at Ambrx, Inc. since 2023, Chairman at PDS Biotechnology Corp.
since 2019, Chairman at Ambrx Biopharma Cayman, Inc. since 2023, Director at Wallace H.
Coulter Foundation, Director at Inflamacore LLC, and Director at Two B Pharma.
Mr. Glover's former job(s) include being the Chairman at Ambrx Biopharma, Inc. from 2023 to 2024, Director at INCON Co., Ltd., Director at Auriga Laboratories, Inc., Senior Vice President-Brand Operations at Andrx Corp.
from 2003 to 2006, Chief Business Officer & Executive Vice President at Insmed, Inc. from 2006 to 2010, President at Insmed Therapeutic Proteins from 2007 to 2009, President & General Manager at Andrx Laboratories, Inc., and President & General Manager at Watson Therapeutics, Inc.Mr. Glover's education history includes undergraduate studies at Illinois State University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PDS BIOTECHNOLOGY CORP.
0.21% | 14/07/2023 | 63 790 ( 0.21% ) | 252 608 $ | 31/03/2024 |
| 21/03/2024 | 18 190 ( 0.24% ) | 13 643 $ | 31/03/2024 | |
| 12/12/2022 | 0 ( nan% ) | - $ | 31/03/2024 |
Cargos activos de Stephen Glover
| Empresas | Cargo | Inicio |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Chairman | - |
| ZYVERSA THERAPEUTICS, INC. | Chief Executive Officer | 01/12/2022 |
| AMBRX INC | Chairman | 01/05/2023 |
| Inflamacore LLC | Director/Board Member | - |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Chairman | 18/05/2023 |
| Wallace H. Coulter Foundation | Director/Board Member | - |
Two B Pharma
 Two B Pharma Pharmaceuticals: GenericHealth Technology Two B Pharma is an Egyptian clinical-stage pharmaceutical company that develops drugs. | Director/Board Member | - |
Asclepius Life Sciences Fund LP
 Asclepius Life Sciences Fund LP Financial ConglomeratesFinance Asclepius Life Sciences Fund LP provides pooled investment funds. The company was founded by Stephen C. Glover and Steven Gerst and is headquartered in New York, NY. | Founder | - |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Chief Executive Officer | 01/03/2014 |
Antiguos cargos conocidos de Stephen Glover.
| Empresas | Cargo | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formación de Stephen Glover.
| Illinois State University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| INSMED INCORPORATED | Health Technology |
| INCON CO.,LTD. | Consumer Durables |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| ZYVERSA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 12 |
|---|---|
Andrx Corp.
 Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | Health Technology |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
| Wallace H. Coulter Foundation | Commercial Services |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Auriga Laboratories, Inc.
 Auriga Laboratories, Inc. BiotechnologyHealth Technology Auriga Laboratories, Inc. is a specialty pharmaceutical company, which is engaged in the commercialization, licensing and development of prescription pharmaceutical products. Its products are focused in the respiratory, dermatology CNS and anti-infective therapeutic categories and are marketed to primary care physicians, pediatricians, dermatologists, urologists, psychiatrists and rheumatologists. The company was founded on April 12, 2005 and is headquartered in Camarillo, CA. | Health Technology |
Andrx Laboratories, Inc.
 Andrx Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Andrx Laboratories, Inc. was a specialty pharmaceuticals company that was acquired by Watson Pharmaceuticals in November 2006. It engaged in the development and commercialization of controlled-release branded pharmaceuticals and generics. The company was founded in 1995 and was headquartered in Fort Lauderdale, FL. | Health Technology |
| Watson Therapeutics, Inc. | |
Asclepius Life Sciences Fund LP
Asclepius Life Sciences Fund LP Financial ConglomeratesFinance Asclepius Life Sciences Fund LP provides pooled investment funds. The company was founded by Stephen C. Glover and Steven Gerst and is headquartered in New York, NY. | Finance |
| Inflamacore LLC | |
Two B Pharma
Two B Pharma Pharmaceuticals: GenericHealth Technology Two B Pharma is an Egyptian clinical-stage pharmaceutical company that develops drugs. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
| Insmed Therapeutic Proteins |
- Bolsa de valores
- Insiders
- Stephen Glover
